News
Academy
Editorial PodcastsEditorial VideosPeer ExchangeProfiles in Medicine
Conference CoverageConference Listing
Pharmaceutical Executive
Partner Perspectives
Content Engagement HubsE-BooksEventsSponsored PodcastsSponsored VideosWebcastsWhitepapers
Subscribe
Corporate CommunicationsCorporate CommunicationsCorporate CommunicationsCorporate CommunicationsCorporate Communications
Direct-to-ConsumerDirect-to-ConsumerDirect-to-ConsumerDirect-to-Consumer
Emerging BiopharmaEmerging BiopharmaEmerging Biopharma
IR Licensing and PartnershipsIR Licensing and PartnershipsIR Licensing and Partnerships
Market AccessMarket AccessMarket AccessMarket Access
Medical AffairsMedical AffairsMedical AffairsMedical Affairs
OperationsOperationsOperationsOperationsOperations
Patient EngagementPatient Engagement
RegulatoryRegulatoryRegulatoryRegulatory
Sales & MarketingSales & MarketingSales & MarketingSales & MarketingSales & Marketing
Spotlight -
  • Latest Executive Roundtables
  • Asembia 2025
  • Sales Effectiveness
IS1
  • Applied Clinical Trials

  • BioPharm International

  • Cannabis Science and Technology

  • Chromatography Online

  • Nutritional Outlook

  • Pharmaceutical Commerce

  • Pharmaceutical Executive

  • Pharm Tech

  • Spectroscopy Online

  • Turbo Machinery Magazine

Corporate CommunicationsCorporate CommunicationsCorporate CommunicationsCorporate CommunicationsCorporate Communications
Direct-to-ConsumerDirect-to-ConsumerDirect-to-ConsumerDirect-to-Consumer
Emerging BiopharmaEmerging BiopharmaEmerging Biopharma
IR Licensing and PartnershipsIR Licensing and PartnershipsIR Licensing and Partnerships
Market AccessMarket AccessMarket AccessMarket Access
Medical AffairsMedical AffairsMedical AffairsMedical Affairs
OperationsOperationsOperationsOperationsOperations
Patient EngagementPatient Engagement
RegulatoryRegulatoryRegulatoryRegulatory
Sales & MarketingSales & MarketingSales & MarketingSales & MarketingSales & Marketing
IS1
  • Applied Clinical Trials

  • BioPharm International

  • Cannabis Science and Technology

  • Chromatography Online

  • Nutritional Outlook

  • Pharmaceutical Commerce

  • Pharmaceutical Executive

  • Pharm Tech

  • Spectroscopy Online

  • Turbo Machinery Magazine

    • Academy
    • Partner Perspectives
    • Subscribe
Advertisement

Feature

Video

October 22, 2024

Pharma Marketing Trends to Expect in 2025

Author(s):

Miranda Schmalfuhs

In this part of her video interview, Amanda Powers-Han, Chief Marketing Officer, Greater Than One and Pharmaceutical Executive Advisory Board Member identifies marketing trends you expect to be big right away in 2025.

In a recent video interview with Pharmaceutical Executive, Amanda Powers-Han, Chief Marketing Officer, Greater Than One and Pharmaceutical Executive Advisory Board Member discussed the importance of patient engagement in pharma marketing. She emphasized the need for personalized marketing strategies that build trust and ensure data privacy. The use of AI and advanced analytics tools was highlighted as crucial for extracting meaningful insights from healthcare data. Powers-Han also addressed the evolving regulatory landscape and the importance of ethical marketing practices in the digital age. Additionally, conversation was had surrounding the challenges of measuring ROI in the pharmaceutical industry and the potential of personalized audio and video content in future marketing efforts.

What are some marketing trends you expect to be big right away in 2025?

One of them is the topic that we were pushing on a little bit earlier in terms of data and omni channel. Omnichannel is something that all of our clients are working very hard to build in terms of what is that omnichannel customer experience, and how do we actually enable that to take place? Different degrees of maturity depending on the client that we're working with, but it is one of the key challenges that every one of our clients is trying to figure out, and something that we're helping them with. The other is big bets on Google and Tiktok, those are going to be huge decisions that are coming up. And depending on the outcome of those decisions, we believe there's going to be some really great positive disruptions that could come from it.

And then in terms of format, and just as we think about, you know, channels and marketing mix, the power of video is just undeniable. And while you know, traditionally, the larger brands were developing TV spots, now there is a huge opportunity for even the smaller niche brands products to invest in video content in so many exciting ways for us to deploy and distribute that video content in the world of digital that we believe that doubling down on video content is both where the industry is headed and it's going to be great for the brands that we support. And then the last one is, you know, as we think about the way that content is created and developing the best customer experience as possible, it's all about fusing content in media and technology to bring those great experiences forward.

So, we believe that in 2025 there's going to be a lot of great work that will continue to be done, and even more so than this year, creating and crafting content for the develop for the environment that it's living in, versus the traditional, you know, create one campaign idea, and then just pull it through in a very direct way across channel. So, I think the more we can do as marketers to think about what customers need and build content that's crafted for the environment is going to make a huge difference in a trend that we're going to see in 25 and it just, it's, you know, this business is more fun than it's ever been. There's just so many new opportunities and innovations that are just, you know, really right for us all to dig into, to lean into, and to figure out together. So, we're excited.

Newsletter

Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.

Subscribe Now!
Related Videos
Gen Li
Gen Li
Gen Li
Dr. Ben Zeskind
Gen Li
Dr. Ben Zeskind
Gen Li
Dr. Ben Zeskind
Related Content
Advertisement
Early Trial Success Signals Promise for GT-02287 in Parkinson’s Disease Treatment
August 1st 2025

Early Trial Success Signals Promise for GT-02287 in Parkinson’s Disease Treatment

Don Tracy, Associate Editor
Gene Mack, CEO, GAIN Therapeutics, shares how growing clinician confidence and strong early experiences helped accelerate enrollment in the company’s Phase Ib Parkinson’s disease trial.
Jennifer Butler
August 1st 2025

The Misinformation Maze: Navigating Public Health in the Digital Age

Miranda Schmalfuhs
Jennifer Butler, chief commercial officer of Pleio, discusses misinformation's threat to public health, where patients are turning for trustworthy health information, the industry's pivot to peer-to-patient strategies to educate patients, and more.
Courtesy Simply Good Foods Co.
August 1st 2025

Survey Shows Positive Impact of GLP-1 Usage on Couples

Mike Hollan
The results showed that people started mirroring the eating habits of GLP-1 users even when they weren’t taking the medication themselves.
Navigating Distrust: Pharma in the Age of Social Media
August 1st 2025

Navigating Distrust: Pharma in the Age of Social Media

Miranda Schmalfuhs
Ian Baer, Founder and CEO of Sooth, discusses how the growing distrust in social media will impact industry marketing strategies and the relationships between pharmaceutical companies and the patients they aim to serve. He also explains dark social, how to combat misinformation, closing the trust gap, and more.
Stock.adobe.com
August 1st 2025

TV & Film Star Aaron Lazar Features NeuroSense CEO Alon Ben-Noon on Special Live ALS Focused Webinar

Nicholas Jacobus
A special live broadcast of award-winning star and CEO’s conversation will focus on advancements and regulations on ALS sciences.
Exploring the Promise of E7386 and Lenvatinib Combination Therapy in Endometrial Carcinoma
August 1st 2025

Exploring the Promise of E7386 and Lenvatinib Combination Therapy in Endometrial Carcinoma

Don Tracy, Associate Editor
Corina Dutcus, SVP, oncology global clinical development lead at Eisai, discusses the potential of the E7386 and lenvatinib combination to address unmet needs in second-line treatment for endometrial carcinoma patients.
Related Content
Advertisement
Early Trial Success Signals Promise for GT-02287 in Parkinson’s Disease Treatment
August 1st 2025

Early Trial Success Signals Promise for GT-02287 in Parkinson’s Disease Treatment

Don Tracy, Associate Editor
Gene Mack, CEO, GAIN Therapeutics, shares how growing clinician confidence and strong early experiences helped accelerate enrollment in the company’s Phase Ib Parkinson’s disease trial.
Jennifer Butler
August 1st 2025

The Misinformation Maze: Navigating Public Health in the Digital Age

Miranda Schmalfuhs
Jennifer Butler, chief commercial officer of Pleio, discusses misinformation's threat to public health, where patients are turning for trustworthy health information, the industry's pivot to peer-to-patient strategies to educate patients, and more.
Courtesy Simply Good Foods Co.
August 1st 2025

Survey Shows Positive Impact of GLP-1 Usage on Couples

Mike Hollan
The results showed that people started mirroring the eating habits of GLP-1 users even when they weren’t taking the medication themselves.
Navigating Distrust: Pharma in the Age of Social Media
August 1st 2025

Navigating Distrust: Pharma in the Age of Social Media

Miranda Schmalfuhs
Ian Baer, Founder and CEO of Sooth, discusses how the growing distrust in social media will impact industry marketing strategies and the relationships between pharmaceutical companies and the patients they aim to serve. He also explains dark social, how to combat misinformation, closing the trust gap, and more.
Stock.adobe.com
August 1st 2025

TV & Film Star Aaron Lazar Features NeuroSense CEO Alon Ben-Noon on Special Live ALS Focused Webinar

Nicholas Jacobus
A special live broadcast of award-winning star and CEO’s conversation will focus on advancements and regulations on ALS sciences.
Exploring the Promise of E7386 and Lenvatinib Combination Therapy in Endometrial Carcinoma
August 1st 2025

Exploring the Promise of E7386 and Lenvatinib Combination Therapy in Endometrial Carcinoma

Don Tracy, Associate Editor
Corina Dutcus, SVP, oncology global clinical development lead at Eisai, discusses the potential of the E7386 and lenvatinib combination to address unmet needs in second-line treatment for endometrial carcinoma patients.
About
Advertise
Contact Us
Editorial Board
Editorial Submission Guidelines
Do Not Sell My Personal Information
Privacy Policy
Terms and Conditions
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.